List of Sanctioned Projects at KIMS Bhubaneswar
Serial No | Project Title | Name of Principal Investigator | Department | Funding Source | Project duration | Date/Year | Project Cost Amount in INR |
---|---|---|---|---|---|---|---|
1 | “PICS: Pre-trial feasibility and attitude assessment in eastern India for universal cervical Cancer Screening” | Dr Soumya Mohaptra | R&D | ICMR | Accepted | ||
2 | Combination of uterine artery pulsatility index (UAPI) in first and second trimester: A novel approach to screen Preeclampsia. | Dr Pramila Jena ICMR 3 year | O&G | ICMR | Accepted | ||
3 | Improved in-hospital injury outcomes with LMIC-driven quality improvement in Trauma systems: Low- resource intervention- packages across three continents | Dr Santosh Rath KIMS, Odisha, India | Orthopaedics | Uk-India International | 6 months | 2021 | |
4 | Section A : "ICMR's National Hospital Based Registry on Venous ThromboEmbolism Disorders" Section B: The role of proinflammatory cytokines and adipokines in predisposing to VTE through Multiomics and immunoassay approach | Dr. Chandan K Ray Mohapatra | CTVS | ICMR | 3 years | 2022 | 58 lakhs |
5 | National Task Force on Tuberculosis | Prof. Sonali Kar | Community Medicine | ICMR | 1 year | 2022 | 32 Lakhs |
6 | An intervention study to increase male participation in the family welfare program in two Districts of Odisha | Prof. Sonali Kar | Community Medicine | ICMR | 1 year | 2022 | INR: 69,62,200 |
7 | Dr. Sakir Ahmed Study on Polio and Non-Polio enterovirus infections in patients with Primary Immunodeficiency Disorders (PIDs) at multiple medical institutes across India – PHASE II | Dr. Sakir Ahmed | Clinical Immunology & Rheumatology | WHO | 1 year | 2022 | INR: 1,79,74,150 |
8 | Catalysing multimorbidity research in Low and Middle Income Countries through a “community of practice” approach: An India –Brazil-UK Initiative | Dr. Pranab Mahapatra | Department of Psychiatry | Indo Brazil | 1 year | 2021 | £142,594 GBP* |
9 | Literature reviews and research gap analysis on social determinants of urban health: how social and gender dynamics in a COVID-19 context affect the prevention and control of infectious diseases of poverty | Dr. Pranab Mohapatra, | Department of Psychiatry | India (PI), Brazil (Co PI) and UK (Co PI) | 3 year | 2021 | 56 lakhs |
10 | Improved in-hospital injury outcomes with LMIC-driven quality improvement in Trauma systems: Low-resource intervention-packages across three continents | Prof. Dr Santosh Rath, KIMS, India | Orthopedics, Director , KIMS collaboration research project | Multi NIHR RESEARCH AND INNOVATION FOR GLOBAL HEALTH TRANSFORMATION Call 4 RIGHT: UNINTENTIONAL INJURY | 6 months | 2019 | 10lakhs |
11 | Micronutrient assessment among school going children 6-16 years of age among 10 urban cities of India: main collaborators KGMC Lucknow | DrSonali Kar Core Investigator: Prof Dr. Shally Avasthi | Community Medicine | Funds: KGMU, Lucknow | 1 year | 24.03.2020 | 9,82,500 |
12 | Phase III Safety and Immunogenicity of an Investigational versus the Licensed Formulation of the Pentavalent Vaccine (DTwP-HepB-Hib) Shan5® when administered as Three Dose Primary Series at 6-8, 10-12 and 14-16 Weeks of Age in Healthy Indian Infants and Safety and Immunogenicity of the Investigational Shan5® Formulation when administered as a Single Booster Dose at 12-24 Months of Age. | DrSonaliKar | Community Medicine | Funded by : Shantha Biotech Sanofi group | 6 Months | 17.09.2019 | 7,00,000 |
13 | A single blind, parallel, randomised Phase-III comparative study to evaluate safety and immunogenicity of two intramuscular doses of inactivated Hepatitis A vaccine administered 6 months apart, in 1-15 year-old healthy Hepatitis A vaccine-naïve children. | Dr SonaliKar | Community Medicine | Biologicals E | 6 months | 22.09.2019 | 5,00,000 |
14 | Harmonized One Health Trans-species and Community Surveillance for Tackling Antibacterial Resistance in India | Dr. Basanti K Pathi, | Microbiology | Funded through INCLEN Trust from BIRAC | 3 years | 2019 | 65,00,000 |
15 | Development of registry of rheumatic diseases across India | Dr Ramnath Misra | Department of Rheumatology | Indian Rheumatology Association | 2019 | 7.11.2019 | 5.85 Lakhs |
16 | Tuberculin sensitivity & Susceptibility to COVID 19 | Dr Ramnath Misra [P.I] Prof. AK Praharaj Prof. Ambika P Mohanty Prof. Dr G.C. Kundu Dr Sakir Ahmed Dr. A. Raj Kumar Patro Dr. B. Ravindran (ILS) | Department of Rheumatology | 1 year | 17.03.2020 | 7.5 Lakhs | |
17 | An intervention study to increases male participation in the family welfare program in two district of Odisha | Dr Sonali Kar (PI) | Community Medicine | ICMR | 2 years | 03.04.2020 | 72 Lakhs |
18 | Improving TB diagnosis at Designated Microscopic Centers by introduction of Quality Management Systems and optimum utilization of rapid molecular diagnostics and its cost implication: Pilot project in New Delhi and Odisha | Odisha site PI Dr. Sonali Kar Core PI: Dr. Shikha Dhawan, Share India | Community Medicine | ICMR | 1 year | 05.11.2019 | 7lakhs |
19 | A multicentre follow-up study to assess the immunological persistence of anti-Vi IgG antibodies at 12, 24 and 36 months post primary dose and to evaluate the immune response to a single booster dose of typhoid Vi conjugate vaccine administered at 36 months post primary dose to 6 months to 45-year-old subjects in both treatment arms who participated In the BECT053 study. | PI Dr. Sonali Kar | Community Medicine | BE sponsored | 1 year | 2019 | 5.6 lakhs |
20 | A multicentre single arm non-comparative Phase-III study to evaluate the safety and tolerability of single intramuscular dose of Biological E’s Vi-capsular Polysaccharide-CRM197 Conjugate Typhoid Vaccine in ≥6 months old infants to 45 years old adults | PI Dr. Sonali Kar | Community Medicine | BE sponsored | 6 months | 12.05. 2020 | 8lakhs |
21 | A Phase 3, Observer-Blind, Randomized, Controlled Study To Determine The Safety And Immunogenicity Of Covovax [Sars-Cov-2 Recombinant Spike Protein Nanoparticle Vaccine (Sars-cov-2 rs) with matrix-m1™ adjuvant] in Indian Adults Protocol No.: ICMR/SII-COVOVAX Version 2.0 | Dr. Sonali Kar Core Investigator: Dr. Sheela Godbole | Community Medicine | ICMR/SII sponsored | 6 months | 20.10.2020 | 32 lakhs |